论文部分内容阅读
目的比较吡贝地尔缓释片与恩他卡朋治疗帕金森病异动症的临床疗效。方法 119例帕金森病异动症患者,随机分为实验组(60例)和常规组(59例)。实验组给予左旋多巴+恩他卡朋治疗,常规组给予左旋多巴+吡贝地尔缓释片治疗。比较两组临床疗效。结果治疗前实验组统一帕金森病评分量表(UPDRS)评分为(4.62±2.014)分,常规组为(4.59±1.958)分,比较差异无统计学意义(P>0.05);治疗后,实验组UPDRS评分为(0.96±0.894)分,低于常规组的(2.10±1.440)分,比较差异具有统计学意义(P<0.05)。结论左旋多巴结合恩他卡朋用于帕金森病异动症治疗的临床效果更加显著,能有效控制患者的临床症状,值得在临床上推广应用。
Objective To compare the clinical effects of piribedil extended release tablets and entacapone in the treatment of Parkinson’s disease. Methods 119 patients with Parkinson’s disease were randomly divided into experimental group (60 cases) and conventional group (59 cases). The experimental group was given levodopa + entacapone treatment, and the conventional group was given levodopa + piribilir sustained-release tablets. The clinical efficacy of the two groups were compared. Results Before treatment, the UPDRS score was (4.62 ± 2.014) in the experimental group and (4.59 ± 1.958) in the conventional group, with no significant difference (P> 0.05). After treatment, the experimental group The UPDRS score was (0.96 ± 0.894) points lower than the control group (2.10 ± 1.440) points, with significant difference (P <0.05). Conclusions The clinical effect of levodopa combined with entecavir for the treatment of Parkinson’s disease is more significant, which can effectively control the clinical symptoms of patients and is worth popularizing in clinical practice.